Literature DB >> 20186231

Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet results.

Xavier Bosch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186231     DOI: 10.1038/nrneph.2010.13

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  5 in total

Review 1.  Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?

Authors:  Xavier Bosch; Antonio Guilabert; Gerard Espinosa; Eduard Mirapeix
Journal:  Trends Immunol       Date:  2008-04-24       Impact factor: 16.687

Review 2.  A perspective on B-cell-targeting therapy for SLE.

Authors:  R John Looney; Jennifer Anolik; Inaki Sanz
Journal:  Mod Rheumatol       Date:  2009-08-08       Impact factor: 3.023

Review 3.  B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

Authors:  Catarina Favas; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2009-12       Impact factor: 20.543

4.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.

Authors:  Kristine P Ng; Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael Ehrenstein; David A Isenberg
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

Review 5.  Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.

Authors:  M Walsh; D Jayne
Journal:  Kidney Int       Date:  2007-07-04       Impact factor: 10.612

  5 in total
  1 in total

Review 1.  Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.

Authors:  Hitoshi Yokoyama; Hiroshi Okuyama; Hideki Yamaya
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.